Also, the effect of survivin siRNA-loaded EVs was confirmed in prostate cancer xenografts, orthotopic breast cancer models, and patient-derived colorectal cancer xenografts, with PSMA aptamer, EGFR aptamer, and folate-surface modification, respectively. This evidence concerns the gene EGFR and breast cancer.